Загрузка...
GUIP1: a R package for dose escalation strategies in phase I cancer clinical trials
BACKGROUND: The main objective of phase I cancer clinical trials is to identify the maximum tolerated dose, usually defined as the highest dose associated with an acceptable level of severe toxicity during the first cycle of treatment. Several dose-escalation designs based on mathematical modeling o...
Сохранить в:
| Опубликовано в: : | BMC Med Inform Decis Mak |
|---|---|
| Главные авторы: | , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7469913/ https://ncbi.nlm.nih.gov/pubmed/32580715 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12911-020-01149-3 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|